Studie av NX-5948 i kombination med andra agenser hos vuxna med B-cellsmaligniteter
En öppen, multricenter Fas 1b/2-studie för att utvärdera säkerheten och effekten av NX-5948 i kombination med andra läkemedel hos vuxna med B-cellsmaligniteter
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
- How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
- The effects of bexobrutideg in the body when taken with these other treatments
- How well bexobrutideg treats CLL or SLL when taken with these other treatments
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Additional Site Contact Information
- Telefonnummer: 415-417-3418
- E-post: clinicaltrials@nurixtx.com
Studieorter
-
-
California
-
Irvine, California, Förenta staterna, 92618
- Har inte rekryterat ännu
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80012
- Rekrytering
- Rocky Mountain Cancer Centers
-
-
Florida
-
Coral Gables, Florida, Förenta staterna, 33146
- Har inte rekryterat ännu
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Har inte rekryterat ännu
- University of Kansas Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89169
- Har inte rekryterat ännu
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Belleville, New Jersey, Förenta staterna, 07109
- Har inte rekryterat ännu
- New Jersey Cancer Care
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97401
- Rekrytering
- Oncology Associates of Oregon
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- Rekrytering
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- SCRI Oncology Partners
-
-
Texas
-
Tyler, Texas, Förenta staterna, 75702
- Rekrytering
- Texas Oncology - Northeast
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ and bone marrow function
- Measurable disease by computed tomography (CT) per iwCLL
- For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
- Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
- Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
- Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
- Previously treated with a BTK degrader
- Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
- Known central nervous system (CNS) lymphoma or leukemia
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: NX-5948 + venetoklax
|
Administered orally once daily as a capsule
Andra namn:
Administered orally once daily as a tablet per prescribing information |
|
Experimentell: NX-5948 + venetoclax + rituximab
|
Administered orally once daily as a capsule
Andra namn:
Administered orally once daily as a tablet per prescribing information Administered as an intravenous (IV) infusion per prescribing information |
|
Experimentell: NX-5948 + venetoklax + obinutuzumab
|
Administered orally once daily as a capsule
Andra namn:
Administered orally once daily as a tablet per prescribing information Administered as an IV infusion per prescribing information |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Antal deltagare med behandlingsrelaterade biverkningar
Tidsram: Upp till cirka 7 år
|
Upp till cirka 7 år
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response rate as determined by investigator
Tidsram: Up to approximately 7 years
|
The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR |
Up to approximately 7 years
|
|
Duration of response as determined by investigator
Tidsram: Up to approximately 7 years
|
Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Progression-free survival as determined by investigator
Tidsram: Up to approximately 7 years
|
Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Complete response rate as determined by investigator
Tidsram: Up to approximately 7 years
|
The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL. |
Up to approximately 7 years
|
|
Time to response as determined by investigator
Tidsram: Up to approximately 7 years
|
Time from the start date of study treatment to the date of the first assessment of a response |
Up to approximately 7 years
|
|
Overall survival
Tidsram: Up to approximately 7 years
|
Time from the start date of study treatment to the date of death from any cause |
Up to approximately 7 years
|
|
Pharmacokinetic profile of NX-5948
Tidsram: Up to approximately 1 year
|
NX-5948 concentrations in blood samples |
Up to approximately 1 year
|
|
Pharmacokinetic profile of venetoclax
Tidsram: Up to approximately 1 year
|
Venetoclax concentrations in blood samples |
Up to approximately 1 year
|
|
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Tidsram: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life |
Baseline and up to approximately 27 months
|
|
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Tidsram: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes |
Baseline and up to approximately 27 months
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Study Director, Nurix Therapeutics, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Lymfom, icke-Hodgkin
- Leukemi, B-cell
- Lymfom
- Leukemi, lymfoid
- Leukemi
- Patologiska tillstånd, tecken och symtom
- Hemiska och lymfsjukdomar
- Lymfom, B-cell
- Leukemi, lymfocytisk, kronisk, B-cell
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Antikroppar, monoklonal, murin härledd
- Rituximab
- venetoklax
- obinutuzumab
Andra studie-ID-nummer
Andra studie-ID-nummer
- NX-5948-203
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .